MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.02
-0.17
-3.28%
Closed 16:00 03/05 EST
OPEN
5.20
PREV CLOSE
5.19
HIGH
5.28
LOW
4.460
VOLUME
235.78K
TURNOVER
--
52 WEEK HIGH
6.07
52 WEEK LOW
1.443
MARKET CAP
136.73M
P/E (TTM)
-14.7214
1D
5D
1M
3M
1Y
5Y
DJ MediWound Price Target Announced at $10.00/Share by Aegis Capital
Dow Jones · 5d ago
DJ MediWound Initiated at Buy by Aegis Capital
Dow Jones · 5d ago
Vericel Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
CAMBRIDGE, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in...
GlobeNewswire · 5d ago
--Analyst Actions: Aegis Capital Reinstates MediWound at Buy with $10 Price Target
MT Newswires · 5d ago
MediWound to Participate in Upcoming March Investment Conferences
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will present at the following virtual investor conferences...
GlobeNewswire · 02/25 21:04
Mediwound (MDWD) Receives a Rating Update from a Top Analyst
SmarterAnalyst · 02/25 18:35
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 02/25 13:45
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 02/25 13:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDWD. Analyze the recent business situations of Mediwound through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDWD stock price target is 7.67 with a high estimate of 10.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 5.22M
% Owned: 19.17%
Shares Outstanding: 27.24M
TypeInstitutionsShares
Increased
8
134.98K
New
8
315.36K
Decreased
8
237.71K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Stephen Wills
Chairman/Executive Director
stephen Wills
Chief Executive Officer
Cal Cohen
Chief Executive Officer
Sharon Malka
Chief Financial Officer
Boaz Gur-Lavie
Executive Vice President/General Counsel/Secretary
Yaron Meyer
Chief Technology Officer
Lior Rosenberg
Other
Ety Klinger
Director
David Fox
Director
Ofer Gonen
Director
Samuel Moed
Director
Assaf Segal
Independent Director
Vickie Driver
Independent Director
Sharon Kochan
Independent Director
Nissim Mashiach
No Data
  • All
  • Financials
  • Insiders
More
About MDWD
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.